SRPT · available-data snapshot
Sarepta Therapeutics, Inc. (SRPT): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Sarepta Therapeutics, Inc. (SRPT); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for SRPT?
We do not publish a fair value for Sarepta Therapeutics, Inc.. What we can say from its filings and market data is below.
What is SRPT's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: trades below our estimate of what it's worth. Its weakest: growth is slow or negative.
- Value · 73 of 100
Cheaper than 73% of Healthcare companies in US
- Price vs worth · 100 of 100
- Quality · 30 of 100
More profitable than 30% of Healthcare companies in US
- Financial health · 55 of 100
Financially stronger than 55% of Healthcare companies in US
- Growth · 6 of 100
Growing faster than 6% of Healthcare companies in US
- Momentum · 30 of 100
Outperformed 30% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $17.43
- Market cap
- $1,
841, 607, 168 - 52-week high
- $24.68
- 52-week low
- $14.68
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Sarepta Therapeutics, Inc. (SRPT) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, SRPT trades at a recent price of $17.43, a market capitalisation of about $1,841,607,168, sitting 28% of the way up its 52-week range ($14.68–$24.68), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing SRPT's trading multiples against a sector benchmark. Here that gives Fwd P/E of 7.3× (cheaper than the peer median of 17.6×); P/B of 1.2× (cheaper than the peer median of 7.9×); P/S of 0.9× (cheaper than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. SRPT shows a price-to-book (P/B) of 1.21 and book value of $14.46 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. SRPT is in a mixed trend, trading -29.4% from its 52-week high. Over the past year the stock is -25.8%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
SRPT vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | SRPT | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 7.3× | 17.6× | cheaper than |
| P/B | 1.2× | 7.9× | cheaper than |
| P/S | 0.9× | 6.2× | cheaper than |
What does Sarepta Therapeutics, Inc. do?
What does it do?
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 835 people.
How does it make money?
The business turns $2.0B in annual revenue into profit. Out of every $100 of sales, about $13 is left as operating profit (operating margin of 13.0%), after a 19% gross margin on the products/services it sells. After all costs, taxes and interest, -6.9% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.7× equity), comfortably covers its short-term bills (4.4× current ratio), and is currently lossmaking.
Who at SRPT filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Wong Ryan Ho-Yan | Chief Financial Officer | Shares withheld (tax) | $294,903.84 | Form 4 for Wong Ryan Ho-Yan (opens sec.gov in a new tab) | |
| Estepan Ian Michael | Chief Operating Officer | Shares withheld (tax) | $551,033.78 | Form 4 for Estepan Ian Michael (opens sec.gov in a new tab) | |
| Rothfuss Cristin | EVP, General Counsel | Shares withheld (tax) | $489,395.50 | Form 4 for Rothfuss Cristin (opens sec.gov in a new tab) | |
| Rodino-Klapac Louise | President, R&D and Tech Ops | Shares withheld (tax) | $476,019.06 | Form 4 for Rodino-Klapac Louise (opens sec.gov in a new tab) | |
| SEVERINO MICHAEL | Director, Chief Executive Officer | Grant / award | — | Form 4 for SEVERINO MICHAEL (opens sec.gov in a new tab) | |
| Boor Kathryn Jean | Director | Grant / award | — | Form 4 for Boor Kathryn Jean (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.